Kanamycin
| Home | | Pharmacology |Chapter: Essential pharmacology : Aminoglycoside Antibiotics
Obtained from S. kanamyceticus (in 1957), it was the second systemically used aminoglycoside to be developed after streptomycin. It is similar to streptomycin in all respects including efficacy against M. tuberculosis and lack of activity on Pseudomonas.
KANAMYCIN
Obtained from S. kanamyceticus (in 1957), it was the second systemically used aminoglycoside to be developed after streptomycin. It is similar to streptomycin in all respects including efficacy against M. tuberculosis and lack of activity on Pseudomonas. However, it is more toxic, both to the cochlea and to kidney. Hearing loss is more common than vestibular disturbance.
Because of toxicity and narrow spectrum of activity, it has been largely replaced by other aminoglycosides for treatment of gram-negative bacillary infections. It is occasionally used as a second line drug in resistant tuberculosis.
Dose: 0.5 g i.m. BD–TDS: KANAMYCIN, KANCIN, KANAMAC 0.5, 1 g inj.
